Applied BioCode Corporation (6598.TW)

TWD 19.05

(-0.52%)

Long Term Debt Summary of Applied BioCode Corporation

Applied BioCode Corporation's latest annual long term debt in 2023 was 18.07 Million TWD , down -45.95% from previous year.
Applied BioCode Corporation's latest quarterly long term debt in 2024 Q2 was 10.6 Million TWD , down 0.0% from previous quarter.
Applied BioCode Corporation reported annual long term debt of 33.44 Million TWD in 2022, down -24.94% from previous year.
Applied BioCode Corporation reported annual long term debt of 44.56 Million TWD in 2021, down -8.56% from previous year.
Applied BioCode Corporation reported quarterly long term debt of 14.5 Million TWD for 2024 Q1, down 0.0% from previous quarter.
Applied BioCode Corporation reported quarterly long term debt of 18.07 Million TWD for 2023 Q4, down -22.71% from previous quarter.

Annual Long Term Debt Chart of Applied BioCode Corporation (2023 - 2012)

Historical Annual Long Term Debt of Applied BioCode Corporation (2023 - 2012)

Year	Long Term Debt	Long Term Debt Growth
2023	18.07 Million TWD	-45.95%
2022	33.44 Million TWD	-24.94%
2021	44.56 Million TWD	-8.56%
2020	48.73 Million TWD	-22.7%
2019	63.04 Million TWD	863.37%
2018	6.54 Million TWD	140.93%
2017	-15.99 Million TWD	0.0%
2016	- TWD	0.0%
2015	- TWD	0.0%
2014	- TWD	0.0%
2013	- TWD	0.0%
2012	- TWD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	10.6 Million TWD	0.0%
2024 Q1	14.5 Million TWD	0.0%
2023 Q4	18.07 Million TWD	-22.71%
2023 FY	18.07 Million TWD	-45.95%
2023 Q2	25.99 Million TWD	-11.42%
2023 Q3	23.39 Million TWD	-10.0%
2023 Q1	29.34 Million TWD	-12.28%
2022 Q1	42.14 Million TWD	-5.43%
2022 Q2	40.19 Million TWD	-4.62%
2022 Q4	33.44 Million TWD	-13.63%
2022 Q3	38.72 Million TWD	-3.66%
2022 FY	33.44 Million TWD	-24.94%
2021 FY	44.56 Million TWD	-8.56%
2021 Q3	43.85 Million TWD	5.57%
2021 Q4	44.56 Million TWD	1.62%
2021 Q1	45.49 Million TWD	-6.65%
2021 Q2	41.53 Million TWD	-8.69%
2020 Q1	61.75 Million TWD	-2.05%
2020 Q2	73.7 Million TWD	19.36%
2020 Q3	63.89 Million TWD	-13.31%
2020 Q4	48.73 Million TWD	-23.73%
2020 FY	48.73 Million TWD	-22.7%
2019 Q1	- TWD	-100.0%
2019 FY	63.04 Million TWD	863.37%
2019 Q3	90.7 Million TWD	-7.71%
2019 Q2	98.27 Million TWD	0.0%
2019 Q4	63.04 Million TWD	-30.5%
2018 Q2	- TWD	0.0%
2018 FY	6.54 Million TWD	140.93%
2018 Q4	6.54 Million TWD	0.0%
2018 Q1	- TWD	0.0%
2017 FY	-15.99 Million TWD	0.0%
2017 Q2	- TWD	0.0%
2017 Q1	- TWD	0.0%
2017 Q3	- TWD	0.0%
2017 Q4	- TWD	0.0%
2016 Q2	- TWD	0.0%
2016 Q4	- TWD	0.0%
2016 FY	- TWD	0.0%
2015 FY	- TWD	0.0%
2015 Q4	- TWD	0.0%
2014 FY	- TWD	0.0%
2013 FY	- TWD	0.0%
2012 FY	- TWD	0.0%

Peer Long Term Debt Comparison of Applied BioCode Corporation

Name	Long Term Debt	Long Term Debt Difference
Excelsior Medical Co., Ltd.	236.82 Million TWD	92.367%
Apex Medical Corp.	141.16 Million TWD	87.194%
OK Biotech Co., Ltd.	94.1 Million TWD	80.79%